Compare up to 40 stocks
Compared Stocks: 1 / 40
| Name | Sector | Price | Volume | Market Cap | P/E Ratio | Dividend Yield | Analyst Consensus | Analyst Price Target | Smart Score | Leveraged ETF | Article | Follow |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
 MEDS | General | $0.74 | 5.94M | $3.34M | -0.04 | ― | ― |
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| MEDS | DataMeds AI | 0.74 | -31.57 | -97.70% |
| Name | Price | % Change | |
|---|---|---|---|
| MEDS | $0.74 | -97.70% |
DataMeds AI (MEDS) announced that it has signed a memorandum of understanding with a Florida-based health maintenance organization, whose name is being withheld at its request, to deploy the Health
An announcement from DataMeds AI ( ($MEDS) ) is now available. On November 3, 2026, DataMEDS AI terminated its Second Amended and Restated Letter of Intent, dated October 19, with
DataMeds AI (MEDS) announced that it has terminated the Second Amended and Restated letter of intent dated October 19 with Datavault AI (DVLT), Data Health Partners, or DHP, wholly-owned subsidiary
DataMeds AI (MEDS) announced that its pharmacy-focused subsidiary Corexa Health has entered into an agreement for commercial supply to bulk drug substance and API of six peptide recommended by the
The latest update is out from DataMeds AI ( ($MEDS) ). On October 21–22, 2026, DataMEDS AI entered into a non-binding Second Amended and Restated Letter of Intent with Datavault
Datavault AI (DVLT) announced that it has entered into a non-binding letter of intent to acquire a 19.9% equity interest in DataMEDS AI (MEDS) in consideration of an expansion of
DataMEDS AI (MEDS) has entered into an amended and restated non-binding letter of intent dated October 19 with Datavault (DVLT) AI, Data Health Partners’ wholly-owned subsidiary REBOOT Health AI, Inc.,
DataMeds AI ( ($MEDS) ) has provided an update. On October 20, 2026, DataMeds AI, Inc., a Tampa-based health technology and pharmacy services company trading on Nasdaq under MEDS, reported
DataMeds AI ( ($MEDS) ) has provided an announcement. On October 13, 2026, DataMeds AI, Inc. entered into an Intellectual Property License and Product and Services Agreement with REBOOT Health
An announcement from DataMeds AI ( ($MEDS) ) is now available. As of October 13, 2026, DataMEDS AI reported stockholders’ equity above $2.5 million following a series of legal and
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.
